TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Bisig et al. [9] also suggested that the expression of CD30 might constitute a valuable criterion to define two distinct biological subgroups [CD30(+) and CD30(−)] within the heterogeneous category of PTCL, NOS with the potential benefits of incorporating anti-CD30 immunoconjugates into the treatment strategies of CD30(+) PTCL.